NEW YORK, NY - Enzo Biochem Inc. announced in a press release that it has reached and finalized a settlement with Agilent Technologies, Inc. (NYSE: A) involving payment of $9 million to Enzo in an infringement action brought by Enzo regarding its U.S. Patent No. 7,064,197.

 

Today’s settlement resolving the disputes between Enzo and Agilent impacts only one of 11 cases originally brought by Enzo in the United States District Court for the District of Delaware alleging patent infringements against various companies, eight of which remain pending.

 

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.